OncoSil + gemcitabine

**OncoSil + gemcitabine** is a combination therapy used for the treatment of patients with *locally advanced unresectable pancreatic cancer*. It consists of **OncoSil**, a device that enables the direct intratumoural placement of phosphorus-32 (32P) microparticles—a form of radiation brachytherapy—and **gemcitabine**, a nucleoside analog chemotherapy agent. OncoSil is designed to deliver a targeted dose of beta radiation directly into the pancreatic tumor, causing DNA damage to cancer cells and inhibiting their division and proliferation, thereby enhancing local tumor control. When used in combination, gemcitabine provides systemic antineoplastic activity, while OncoSil delivers localized radiotherapeutic effects. This combination has been studied in multiple clinical studies (including the PanCO and OncoPac-1 trials), demonstrating an acceptable safety profile and clinical benefit in disease control, progression-free survival, and overall survival for patients with locally advanced pancreatic cancer not suitable for resection[1][2][3][4][5][6][7].

Other names

OncoSil plus gemcitabineOncoSil + gemcitabine chemotherapy